- Home
- LRE vs UNCY Comparison
LRE vs UNCY Comparison
Compare LRE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | UNCY |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 150.1M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LRE | UNCY |
|---|---|---|
| Price | $1.00 | $4.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 9.3K | ★ 743.2K |
| Earning Date | 07-30-2015 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $3.72 |
| 52 Week High | $1.86 | $8.74 |
Technical Indicators
Market Signals| Indicator | LRE | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 26.21 | 38.41 |
| Support Level | N/A | $3.93 |
| Resistance Level | $1.33 | $5.86 |
| Average True Range (ATR) | 0.03 | 0.22 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 33.87 | 9.00 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.